Satellos Bioscience Inc. cash flow statement MSLE

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Satellos Bioscience Inc. used $23.6 million of cash from operations. It spent $6,000 on capital expenditures. Free cash flow was negative, at -$23.6 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line
FY 2025
Dec 31, 2025
Operating
Operating cash flow
-24
Investing
Capital expenditures
0
Investing cash flow
-9
Financing
Financing cash flow
2
Change in cash
Effect of exchange rate
1
Net change in cash
-30
Free cash flow
-24
Per share
Free cash flow per share
-1.62
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MSLE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Canada (Federal Level)
Headquarters
Markham
SEC filer status
, Emerging growth company
SEC CIK
1421642
Former names
ICO THERAPEUTICS INC (until Sep 10, 2019)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.